<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159066</url>
  </required_header>
  <id_info>
    <org_study_id>CLGX818X2109</org_study_id>
    <secondary_id>C4221013</secondary_id>
    <secondary_id>2013-004552-38</secondary_id>
    <nct_id>NCT02159066</nct_id>
  </id_info>
  <brief_title>LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma</brief_title>
  <acronym>LOGIC-2</acronym>
  <official_title>The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in&#xD;
      combination with targeted agents after progression on LGX818/MEK162 combination therapy, as&#xD;
      well as the safety and tolerability of the novel triple combinations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts: in Part I/Run-In, patients naïve to selective BRAF and MEK&#xD;
      inhibitors will be treated with the LGX818/MEK162 combination until disease progression (as&#xD;
      defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that&#xD;
      time, patients will enter Part II of the study for tailored combination treatment in one of&#xD;
      four arms of LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011 Patients with BRAF&#xD;
      mutant melanoma treated by LGX818/MEK162 combination in other studies can be enrolled&#xD;
      directly in Part II of CLGX818X2109 after relapse.&#xD;
&#xD;
      Dose-escalations in the combination arms for which no MTD has been established will be based&#xD;
      on the recommendations of a Bayesian logistic regression model guided by an escalation with&#xD;
      overdose control criterion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 23, 2014</start_date>
  <completion_date type="Anticipated">January 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) (Part II)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>2 years</time_frame>
    <description>in Cycle 1 of Combination Part (Part II); cycle 1 = 21 days or 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) parameters of LGX818 + MEK162 and triple combination partners</measure>
    <time_frame>2 years</time_frame>
    <description>AUCtau, ss; Cmax; Cmax, ss; Tmax; Tmax, ss; Ctrough; Clast, ss; T1/2, ss; CL,ss/F; Vz,ss/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) (Part II)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)(Part I and II)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) (Part I and II)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Part II)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular status</measure>
    <time_frame>baseline, at progression with LGX818 + MEK162 combination treatment up to 2 years</time_frame>
    <description>Molecular Status includes mutation, amplification, expression of markers relevant to the RAF/MEK/ERK and PI3K/AKT pathways</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) (Part I and II)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) (Part I and II)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>LGX818 + MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + MEK162 + LEE011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + MEK162 + BGJ398</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + MEK162 + BKM120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + MEK162 + INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGX818</intervention_name>
    <description>Combination of LGX818 and MEK162 (Part I)</description>
    <arm_group_label>LGX818 + MEK162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>Combination of LGX818 and MEK162 (Part I)</description>
    <arm_group_label>LGX818 + MEK162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>Combination of LGX818 + MEK162 + LEE011 (Part II)</description>
    <arm_group_label>LGX818 + MEK162 + LEE011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGJ398</intervention_name>
    <description>Combination of LGX818 + MEK162 + BGJ398 (Part II)</description>
    <arm_group_label>LGX818 + MEK162 + BGJ398</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>Combination of LGX818 + MEK162 + BKM120 (Part II)</description>
    <arm_group_label>LGX818 + MEK162 + BKM120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>Combination of LGX818 + MEK162 + INC280 (Part II)</description>
    <arm_group_label>LGX818 + MEK162 + INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically confirmed diagnosis of unresectable stage III or metastatic melanoma&#xD;
             (stage IIIC to IV per American Joint Committee on Cancer [AJCC])&#xD;
&#xD;
          -  Documented evidence of BRAF V600 mutation.&#xD;
&#xD;
          -  Newly obtained tumor biopsy at baseline, and patient agrees to a mandatory biopsy at&#xD;
             the time of progression, if not medically contraindicated.&#xD;
&#xD;
          -  Evidence of measurable disease, as determined by RECIST v1.1.&#xD;
&#xD;
        INCLUSION CRITERIA for triple combinations:&#xD;
&#xD;
        Progressive disease following prior treatment with LGX818/MEK162 combination. PRINCIPAL&#xD;
        EXCLUSION CRITERIA Symptomatic or untreated leptomeningeal disease.&#xD;
&#xD;
          -  Symptomatic brain metastases. Patients previously treated or untreated for brain&#xD;
             metastases that are asymptomatic in the absence of corticosteroid therapy or on a&#xD;
             stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be&#xD;
             stable at least 4 weeks with verification by imaging (e.g. brain MRI completed at&#xD;
             screening demonstrating no current evidence of progressive brain metastases). Patients&#xD;
             are not permitted to receive enzyme inducing anti-epileptic drugs.&#xD;
&#xD;
          -  Patients who have developed brain metastases during Part I of the study may continue&#xD;
             to Part II upon discussion with Novartis Medical Monitor. The brain metastasis must be&#xD;
             either asymptomatic or treated and stable for at least 4 weeks and on a stable or&#xD;
             tapering dose of steroids for at least 2 weeks. Patients with brain metastasis are not&#xD;
             eligible for the combination with LEE011.&#xD;
&#xD;
          -  Known acute or chronic pancreatitis.&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity&#xD;
             or hypercoagulability syndromes);&#xD;
&#xD;
          -  Clinically significant cardiac disease including any of the following:&#xD;
&#xD;
          -  CHF requiring treatment (NYH grade ≥ 2),&#xD;
&#xD;
          -  LVEF &lt; 50% as determined by MUGA scan or ECHO&#xD;
&#xD;
          -  History or presence of clinically significant ventricular arrhythmias or atrial&#xD;
             fibrillation&#xD;
&#xD;
          -  Clinically significant resting bradycardia&#xD;
&#xD;
          -  Unstable angina pectoris ≤ 3 months prior to starting study drug&#xD;
&#xD;
          -  Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug,&#xD;
&#xD;
          -  QTcF &gt; 480 msec. Patients with any of the following laboratory values at&#xD;
&#xD;
        Screening/baseline:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1,500/mm3 [1.5 x 109/L]&#xD;
&#xD;
          -  Platelets &lt; 100,000/mm3 [100 x 109/L]&#xD;
&#xD;
          -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x ULN or calculated or directly measured CrCl &lt; 50% LLN (lower&#xD;
             limit of normal)&#xD;
&#xD;
          -  Serum total bilirubin &gt;1.5 x ULN&#xD;
&#xD;
          -  AST/SGOT or ALT/SGPT &gt; 2.5 x ULN, or &gt; 5 x ULN if liver metastases are present&#xD;
&#xD;
        Additional exclusion criteria for the triple combinations:&#xD;
&#xD;
        LGX818/MEK162/BKM120:&#xD;
&#xD;
          -  Patients with fasting glucose &gt; 120 mg/dL or 6.7 mmol/L, and HbA1c &gt; 8 %.&#xD;
&#xD;
          -  Patient has any of the following mood disorders as judged by the&#xD;
&#xD;
        Investigator or a Psychiatrist:&#xD;
&#xD;
          -  Patient has a score ≥ 12 on the PHQ-9 questionnaire&#xD;
&#xD;
          -  Patient has ≥ CTCAE grade 3 anxiety&#xD;
&#xD;
        LGX818/MEK162/BGJ398:&#xD;
&#xD;
          -  History and/or current evidence of significant ectopic mineralization/ calcification&#xD;
             with the exception of calcified lymph nodes and asymptomatic vascular calcification.&#xD;
&#xD;
          -  Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/&#xD;
             band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivits etc.,&#xD;
             confirmed by ophthalmologic examination&#xD;
&#xD;
        LGX818/MEK162/LEE011:&#xD;
&#xD;
          -  Patients with uncontrolled hypertension (please refer to WHO-ISHguidelines) are&#xD;
             excluded from study.&#xD;
&#xD;
          -  QTcF &gt;450 ms for males and &gt;470 ms for females Congenital long QT syndrome or family&#xD;
             history of unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3 and&#xD;
             magnesium levels below the clinically relevant lower limits at study entry&#xD;
&#xD;
          -  Current evidence of brain metastasis or brain metastasis detected by mandatory CT/MRI&#xD;
             at screening&#xD;
&#xD;
          -  PT/INR or aPTT &gt; 1.5xULN&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doris Stein Research Center Building</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Dermatology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Oncology Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Radiology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Attn: Geny O'neill</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Inpatient Hospital &amp; Main Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center- Outpatient Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing 2</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Research Pharmacy Services</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East St Kilda Eye Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3183</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis-Jewish General Hospital</name>
      <address>
        <city>Monteral</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg PPDS</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München</name>
      <address>
        <city>Muenchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Monaldi</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Oncologia Medica e Terapie Innovative Dipartimento di Melanoma IRCCS Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona Cataluna</city>
        <state>Barcelona</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX2 7JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infigratinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

